<br /> Experts are having a lively debate over a booming cancer treatment field called 'precision oncology.'<br />Drugs can be custom-tailored to fit the genetic makeup of cancerous tumors.<br />The FDA has endorsed the first “tissue-agnostic” immunotherapy drug.<br />It's now approved for any advanced solid tumor with flaws in genes that repair DNA.<br />But detractors say the number of patients targeted cancer therapies could benefit is small. <br />
